A haematological malignancy known as chronic lymphocytic leukaemia (CLL) is characterised by an abnormally high rate of white blood cell proliferation. B-cell lymphocytes, which are involved in the production of antibodies to fight against infections and foreign antigens, are the cells most commonly impacted by CLL. The unmet market demand for better therapeutics is demonstrated by the rising incidence of Chronic Lymphocytic Leukemia Therapeutics Market and the high mortality rate. More than 14,000 new cases and more than 4,500 fatalities are anticipated in 2015, according to the American Cancer Society (ACS). CLL is more prevalent in the elderly population, with a higher frequency in those who are 70 or older.
Read More @ https://cmiinfonest.blogspot.com/2022/11/chronic-lymphocytic-leukemia.html
0
